RELX Stock Analysis: Relx | NYSE
Specialty Business Services | NYSE, USA | Market Cap: 56.752m USD | 12M Return: -36.4% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 88.4M
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
RELX PLC is a London-headquartered information analytics company that provides data-driven decision tools to professional and business customers across North America, Europe, and other international markets. The company operates through four reporting segments: Risk, Scientific Technical & Medical, Legal, and Exhibitions, each focused on a distinct professional customer base such as insurers, scientists, healthcare providers, lawyers, and event organizers. Its business model centers on aggregating proprietary and third-party content and combining it with proprietary technology and algorithms to deliver subscription-based analytics and workflow tools.
Classified within the GICS Industrials sector under the Research & Consulting Services sub-industry, RELX is a large-cap issuer traded on the NYSE via an ADR under the ticker RELX, with an IPO dating to October 1994. The company traces its origins to 1903 and was formerly known as Reed Elsevier PLC before adopting its current name in July 2015.
- Exhibitions segment revenue rebounds as trade show attendance normalizes
- Risk segment subscription revenue grows on insurance analytics demand
- AI product launches at Lexis and Elsevier expand margins
- Sterling weakness lifts reported revenue from North American operations
| Net Income: 2.06b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.20 > 0.02 and ΔFCF/TA 2.47 > 1.0 |
| NWC/Revenue: -31.67% < 20% (prev -28.85%; Δ -2.82% < -1%) |
| CFO/TA 0.20 > 3% & CFO 2.90b > Net Income 2.06b |
| Net Debt (7.29b) to EBITDA (3.89b): 1.87 < 3 |
| Current Ratio: 0.49 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.83b) vs 12m ago -3.31% < -2% |
| Gross Margin: 64.99% > 18% (prev 65.02%; Δ -0.03% > 0.5%) |
| Asset Turnover: 64.02% > 50% (prev 62.34%; Δ 1.68% > 0%) |
| Interest Coverage Ratio: 10.17 > 6 (EBIT TTM 3.03b / Interest Expense TTM 297.5m) |
| A: -0.21 (Total Current Assets 2.95b - Total Current Liabilities 5.98b) / Total Assets 14.7b |
| B: 0.13 (Retained Earnings 1.89b / Total Assets 14.7b) |
| C: 0.20 (EBIT TTM 3.03b / Avg Total Assets 14.9b) |
| D: 0.19 (Book Value of Equity 2.36b / Total Liabilities 12.3b) |
| Altman-Z'' = 0.63 = B |
| DSRI: 0.99 (Receivables 2.46b/2.47b, Revenue 9.56b/9.43b) |
| GMI: 1.00 (GM 65.02% / 64.99%) |
| AQI: 1.00 (AQ_t 0.79 / AQ_t-1 0.79) |
| SGI: 1.01 (Revenue 9.56b / 9.43b) |
| TATA: -0.06 (NI 2.06b - CFO 2.90b) / TA 14.7b) |
| Beneish M = -3.04 (Cap -4..+1) = AA |
As of July 14, 2026, the stock is trading at USD 33.42 with a total of 4,387,545 shares traded. Over the past week, the price has changed by +3.56%, over one month by +1.77%, over three months by -0.51% and over the past year by -36.41%.
Current recommended Stop Loss: 32.20 (which is 3.7% or 1.5 ATR below the current price).
Relx has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy RELX.
- StrongBuy: 1
- Buy: 0
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 52.5 | 56.9% |
Market Cap GBP = 42.4b (56.8b USD * 0.7474 USD.GBP)
P/E Trailing = 21.9189
P/E Forward = 17.1821
P/S = 5.9178
P/B = 18.1701
P/EG = 1.3219
Revenue TTM = 9.56b GBP
EBIT TTM = 3.03b GBP
EBITDA TTM = 3.89b GBP
Long Term Debt = 5.63b GBP (from longTermDebt, last quarter)
Short Term Debt = 1.60b GBP (from shortTermDebt, last quarter)
Debt = 7.42b GBP (from shortLongTermDebtTotal, last quarter) + Leases 97.0m
Net Debt = 7.29b GBP (calculated: Debt 7.42b - CCE 130.8m)
Enterprise Value = 49.7b GBP (42.4b + Debt 7.42b - CCE 130.8m)
Interest Coverage Ratio = 10.17 (Ebit TTM 3.03b / Interest Expense TTM 297.5m)
EV/FCF = 17.24x (Enterprise Value 49.7b / FCF TTM 2.88b)
FCF Yield = 5.80% (FCF TTM 2.88b / Enterprise Value 49.7b)
FCF Margin = 30.15% (FCF TTM 2.88b / Revenue TTM 9.56b)
Net Margin = 21.53% (Net Income TTM 2.06b / Revenue TTM 9.56b)
Gross Margin = 64.99% ((Revenue TTM 9.56b - Cost of Revenue TTM 3.35b) / Revenue TTM)
Gross Margin QoQ = 63.75% (prev 66.25%)
Tobins Q-Ratio = 3.37 (Enterprise Value 49.7b / Total Assets 14.7b)
Interest Expense / Debt = 4.01% (Interest Expense 297.5m / Debt 7.42b)
Taxrate = 24.43% (669.7m / 2.74b)
NOPAT = 2.29b (EBIT 3.03b * (1 - 24.43%))
Current Ratio = 0.49 (Total Current Assets 2.95b / Total Current Liabilities 5.98b)
Debt / Equity = 3.14 (Debt 7.42b / totalStockholderEquity, last quarter 2.36b)
Debt / EBITDA = 1.87 (Net Debt 7.29b / EBITDA 3.89b)
Debt / FCF = 2.53 (Net Debt 7.29b / FCF TTM 2.88b)
Total Stockholder Equity = 2.81b (last 4 quarters mean from totalStockholderEquity)
RoA = 13.78% (Net Income 2.06b / Total Assets 14.7b)
RoE = 73.28% (Net Income TTM 2.06b / Total Stockholder Equity 2.81b)
RoCE = 35.87% (EBIT 3.03b / Capital Employed (Equity 2.81b + L.T.Debt 5.63b))
RoIC = 22.39% (NOPAT 2.29b / Invested Capital 10.2b)
WACC = 6.63% (E(42.4b)/V(49.8b) * Re(7.26%) + D(7.42b)/V(49.8b) * Rd(4.01%) * (1-Tc(0.24)))
Discount Rate = 7.26% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -89.89 | Cagr: -2.44%
[DCF] Terminal Value 76.81% ; FCFF base≈2.76b ; Y1≈3.04b ; Y5≈3.85b
[DCF] Fair Price = 29.45 (EV 58.8b - Net Debt 7.29b = Equity 51.5b / Shares 1.75b; r=8.35% [WACC [floored]]; 5y FCF grow 11.38% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.0 | # QB: 0
Revenue Correlation: 98.56 | Revenue CAGR: 2.25% | SUE: N/A | # QB: 0
EPS current Year (2026-12-31): EPS=1.90 | Chg30d=-2.11% | Revisions=-50% | GrowthEPS=+9.0% | GrowthRev=+5.5%
EPS next Year (2027-12-31): EPS=2.13 | Chg30d=-1.83% | Revisions=-50% | GrowthEPS=+12.1% | GrowthRev=+6.5%
[Analyst] Revisions Ratio: -67% (up=0, down=6)